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Introduction
Stroke or cerebrovascular disease (CVD), also known
as cerebrovascular accident or apoplexy, ranks as the
third leading cause of death in men and women in
Taiwan. It is also the leading cause of major adult dis-
ability. Stroke is an uncommon event in young women
of childbearing age. However, it has serious conse-
quences, including long-term disability and death, in
young women with newborns or unborn babies. Since
stroke risk factors and pathophysiology are unique to
women, especially during pregnancy and postpartum,
we have reviewed the literature on pregnancy-related
stroke including epidemiology, underlying pathophysi-
ological mechanisms, diagnostic investigation, classifi-
cation, and current management principles.
Epidemiology
The estimated rate of all strokes in pregnant women
varies from 4 to 26 per 100,000 compared with 3 to 10
per 100,000 in non-pregnant women [1]. The incidence
of stroke during pregnancy and puerperium in Taiwanese
women is reported to be 46.2 and 21.47 cases per
100,000 [2,3], respectively. There is a variable incidence
among different stroke subtypes. Per 100,000 popula-
tion, arterial ischemic stroke, venous ischemic stroke, and
intracranial hemorrhage number 4, 10, and 4, respec-
tively [1]. The relative risk of hemorrhagic and ischemic
strokes persists for 12 months postpartum [3]. These
important findings suggest that pre-eclampsia and
eclampsia patients should be followed up for at least
the first year postpartum to reduce stroke occurrence.
Risk Factors and Pathophysiology
Illnesses associated with stroke during pregnancy include
hypertension, diabetes, heart disease, smoking, and
thrombophilia. Multiparity, increased gestational age,
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increased maternal age, strenuous labor, and cesarean
delivery all appear to be risk factors of stroke. There
are specific complications of pregnancy that may cause
stroke. One of these complications, amniotic fluid em-
bolism, is a catastrophic syndrome that can affect the
brain and lead to profound neurological dysfunction
(Figure 1).
The precise pathophysiology connecting CVD to
pregnancy remains unclear. If the pathophysiology is
known, it is possible to identify women at stroke risk
prior to pregnancy and further develop rational preven-
tative intervention. Research has focused on endo-
thelial dysfunction for pregnancy-related stroke. Cerebral
endothelial dysfunction has been demonstrated in a
transcranial ultrasound study [4]. An increased propen-
sity for thrombosis is another factor in the setting of
peripartum stroke. In a study of 12 women with tran-
sient neurologic deficits during pregnancy, an inherited
thrombophilia was identified in 10 women (83%) [5].
Oxidative stress and maternal systemic inflammatory
response may be involved in pregnancy-related stroke
[6]. In a nationwide US case-control study, data indi-
cated a strong correlation between active peripartum
migraines and vascular events including stroke [7].
Diagnostic Investigation
Neuroimaging approaches are important for probing
the underlying vascular etiology in stroke patients. For
urgent evaluation, cranial computed tomography (CT)
may be performed with proper abdominal/pelvic shield-
ing if the benefit outweighs the risk. CT is useful in sep-
arating ischemic from hemorrhagic stroke. However,
the use of radiation during pregnancy should be kept
to a minimum. Brain magnetic resonance imaging
(MRI) is a preferred tool used during pregnancy, al-
though teratogenic effects have been observed in preg-
nant mice exposed to a strong static magnetic field for
short periods of time [8]. Gadolinium is a paramagnetic
contrast agent used to enhance MRI images. The Food
and Drug Administration (FDA) labeled it as a pregnancy
category C because of a lack of epidemiological stud-
ies. In a prospective cohort study, 26 pregnant women
exposed to gadolinium derivatives in the preconception
and first trimester period did not appear to have any
adverse effects during pregnancy or in the neonatal
outcome [9].
One of the most common concerns about cerebral
angiography during pregnancy is the potential risk of
fetal malformation attributed to radiation exposure.
Nevertheless, the benefits of angiography outweigh the
risks. MRI arteriography and venography are non-invasive
and radiation-free examinations that disclose intracra-
nial aneurysm and cerebral venous thrombosis (CVT),
respectively. If intracranial aneurysm needs to be
treated, endovascular angiographic intervention has
been reported to exhibit a low relative risk of radiation
exposure to the fetus [10].
Extracranial and intracranial Doppler scans can serve
as non-invasive studies to assess the status of cerebro-
vascular circulation. Sequential follow-up is easily per-
formed to monitor disease progression and further
measures hemodynamic conversion after intervention.
Evaluation for a patent foramen ovale is an impor-
tant part of the cardiac assessment for a pregnant
woman with an ischemic stroke, especially if hyperco-
agulopathy is identified. However, many cardiologists
feel uncomfortable with administering microbubbles
because of the theoretical potential for an air embolus
Taiwan J Obstet Gynecol • December 2010 • Vol 49 • No 4396
S.J. Cheng, et al
A B
Figure 1. Fatal amniotic fluid embolism in a 26-year-old pregnant woman. (A) Air embolism and (B) bilateral thalamic low
attenuation density are consistent with the postmortem diagnosis.
reaching the fetal circulation. In the setting of sus-
pected hypercoagulopathy, investigations should be
carried out for anticardiolipin, lupus anticoagulant,
protein C, protein S, antithrombin III, d-dimer, and
factor V Leiden.
Classification of CVD
In addition to arterial and venous occlusive strokes,
intracranial hemorrhagic events including intracranial
hemorrhage (Figure 2) and subarachnoid hemorrhage
can develop during pregnancy. There are many causes of
intracranial hemorrhage and subarachnoid hemorrhage
during pregnancy. In one study, eclampsia accounted
for 44% of the cases [11].
Most pregnancy-related strokes occur in the third
trimester and puerperium, and this is especially true for
CVT [11,12] (Figure 3). CVT remains the leading cause
of direct maternal death in the UK, with a four-fold
increased incidence compared with that of the non-
pregnant population [13]. Most clinical manifestations
of CVT are distinct from arterial occlusive stroke. The
onset is not acute. Moreover, headaches may be the only
symptoms in patients with CVT [14]. Therefore, CVT is
sometimes under-recognized and is under-treated.
In many studies, pre-eclampsia/eclampsia and
pregnancy-related hypertension have been associated
with ischemic and hemorrhagic strokes during preg-
nancy [15,16]. Hypertension-related cerebral vascu-
lopathy may represent several different entities, but
might share the same pathophysiology. These include
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Figure 2. Cerebellar hemorrhage with brainstem compression in a 35-year-old pregnant woman. T2 fluid-attenuated inver-
sion recovery magnetic resonance imaging (A) before removal of a hematoma and (B) after removal of hematoma show a
substantial improvement of compression.
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Figure 3. Cerebral venous thrombosis complicated with hemorrhagic transformation in a 29-year-old pregnant woman. 
(A) Computed tomography before craniotomy and (B) T2 weighted imaging after decompressive surgery show a significant
reduction of compressive effect.
posterior reversible encephalopathy syndrome, revers-
ible cerebral vasoconstriction, and postpartum angio-
pathy. Posterior reversible encephalopathy syndrome
may result from endothelial dysfunction and failure 
of cerebral autoregulation with subsequent of vaso-
genic edema. Postpartum angiopathy, a subtype of
reversible cerebral vasoconstriction, also involves re-
versible vasoconstriction, and may be more commonly
associated with ischemic stroke than with cerebral
edema. Diffusion-weighted imaging can differentiate
between vasogenic edema and cytotoxic edema. 
Cytotoxic edema indicates the propensity to ischemic
infarction [17].
Acute Treatment of Stroke During
Pregnancy
Tissue plasminogen activator (tPA) has been approved
for the treatment of acute ischemic stroke with symp-
toms confirmed to be less than 3 hours. Fundamental
harmful considerations of tPA in pregnancy include
potential teratogenicity, placental bleeding/abruption,
premature labor, peripartum uterine bleeding, and post-
partum hemorrhage. Discrepant results from case re-
ports on tPA treatment during pregnancy [18,19] clearly
indicate further investigation. The decision to treat with
tPA in pregnant women is still debatable because of
limited information.
Both low-molecular-weight heparin (LMWH) and
unfractionated heparin do not cross the placenta, and
several reports have indicated a lack of adverse fetal
effects. LMWH has an advantage over unfractionated
heparin because it has a longer half-life, greater bio-
availability, and decreased affinity for heparin-binding
proteins [20]. Currently, it is unclear if it is safe to use
LMWH with acute arterial stroke. However, LMWH is
generally accepted for patients with CVT because it does
not increase the likelihood of cerebral hemorrhagic
complications. LMWH is safe for the fetus because it
does not cross the placenta. Although no randomized
controlled trials have been conducted for pregnant
women with CVT to guide decision making, benefits
should be obtainable by reducing thrombotic progres-
sion and balancing the small risk of bleeding.
To improve neurological outcome, an unstable preg-
nant stroke patient may require transfer to a neurologic
intensive care unit. The use of comprehensive monitor-
ing can provide extensive care for the most complicated
cases. Urgent evaluation and intervention is of para-
mount importance to prevent the human brain from
being rapidly and permanently injured. When cardiopul-
monary arrest occurs, perimortem cesarean delivery
must proceed to increase the chances of maternal and
fetal survival.
In patients with massive cerebral infarction and im-
pending herniation, early decompressive craniotomy
can reduce mortality and increase the likelihood of
favorable outcome [21]. Decompressive surgery is a
challenging task in dealing with pregnant women with
stroke. A previous study found that in a patient with
intracerebral hemorrhage secondary to cerebral sinus
thrombosis who was pregnant for 12 weeks, neurologic
outcome was considerably improved after decompres-
sive craniotomy was carried out [22].
Preventive Treatment of Stroke During
Pregnancy and Lactation
Because pregnancy is a period of increased risk of
intracranial thrombotic and hemorrhagic events, pro-
phylaxis should be used for subsequent pregnancies
following a stroke event. Although the risk of recurrent
CVT seems to be low, this should not have a negative
impact on stroke prevention [23]. Benefits from stroke
prevention will counterbalance the risk from pharma-
cological therapy. Caution should be exhibited during
the prescription of drugs, particularly concerning terato-
genicity, tocolytic actions to prolong labor, and post-
partum women attempting to breast feed.
Women with a history of cardiac valve replacement
or atrial fibrillation often receive long-term anticoagu-
lant therapy for stroke prevention. Ideally, prescribing
anticoagulants to pregnant women should be redun-
dant for the majority of clinicians who concern about
bleeding event during peripartum. Risk and benefit
should be balanced for maternal and fetal concerns.
Unlike LMWH, warfarin can cross the placenta and
thereby pose the risk of teratogenicity. Thus, warfarin
is the mainstay of anticoagulants only for postpartum
stroke prevention. Furthermore, warfarin does not
provoke anticoagulant effects in the breast-fed infant.
Therefore, warfarin can be given to a nursing mother.
An international normalized ratio of 2.0–3.0 is the
optimal goal for patients taking warfarin.
Substituting warfarin with LMWH between 6 and 12
gestational weeks reduces the risk of teratogenicity [24].
Because patients with mechanical heart valves are at
increased risk for thrombotic and hemorrhagic transfor-
mation following a stroke event, aggressive monitoring
of clinical features instead of the international normal-
ized ratio is warranted in pregnant women undergoing
therapy with LMWH [25]. Vaginal delivery without the
Valsalva maneuver is favored to avoid bleeding compli-
cations in pregnant women with anticoagulant therapy.
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Aspirin is widely used in stroke prevention in non-
pregnant women. Aspirin is likely to be safe at a dose
less than 150 mg during the second and third trimesters,
based on current evidence. However, the safety of higher
doses of aspirin during the first trimester remains unclear
[26]. Low doses of aspirin have also been assessed for
use in prevention of pre-eclampsia and its consequences
[27]. According to a survey of 230 clinicians, most of
them agreed that women with a stroke history received
stroke prevention during the first trimester. However,
there is great disagreement among clinicians with
regard to the candidate drug [28]. Although aspirin 
is secreted in breast milk in low concentrations, no
adverse effects have been reported. The American
Academy of Pediatrics has suggested cautious use of
aspirin during lactation [29].
Aspirin increases the likelihood of peptic ulcer dis-
ease. Clopidogrel or ticlopidine can be an alternative
anti-platelet during pregnancy. Because of very limited
information on the use of those two drugs in pregnancy,
no conclusion has been reached regarding the effects
on the fetus. One case report has described a patient
with a past history of myocardial infarction treated
with clopidogrel through pregnancy without any 
complications [30].
Hypertension is one of the most common risk factors
for atherosclerosis. In general, maternal adverse effects
from all drugs for treating hypertension are not differ-
ent from those in non-pregnant women. Antihyperten-
sive drugs may cross the placenta and are categorized
according to the level of risk to the fetus. Only limited
controlled trials have been conducted, and most of
them are classified as FDA category C, which suggests
that drugs should be given only if the potential benefit
justifies the potential risk to the fetus [31]. According
to a study of 139,681 postmenopausal women, women
who breastfed their babies for more than 1 year were 10%
less likely to have a heart attack or stroke than women
who never breastfed. This study encourages women to
breastfeed their infants to reduce the risk of stroke
[32]. The Table shows the FDA categories and lactation
safety for antihypertensive drugs during pregnancy.
Conclusion
It is crucial to identify, at an early stage, pregnant women
suffering from stroke or CVD. Accordingly, prompt inter-
vention may diminish morbidity/mortality and promote
functional outcomes. For pregnant women with stroke
events, an obstetrician will be the first physician that
they encounter. It is important to have an awareness of
stroke for every obstetrician.
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